Alcobra Ends Development Of MDX For Adult ADHD, Ponders Strategic Direction

Failing to meet the primary endpoint in its second Phase III study in adult ADHD, the Israeli firm confirms there is no path forward in that indication. Developing MDX for Fragile X syndrome and business development options are under consideration.